| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.077 | 0.1 |
| mRNA | BRD-K26531177 | CTRPv2 | pan-cancer | AAC | 0.055 | 0.1 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.056 | 0.1 |
| mRNA | alvocidib | CTRPv2 | pan-cancer | AAC | 0.073 | 0.1 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | -0.082 | 0.1 |
| mRNA | MST-312 | CTRPv2 | pan-cancer | AAC | 0.052 | 0.1 |
| mRNA | CAY10594 | CTRPv2 | pan-cancer | AAC | 0.056 | 0.1 |
| mRNA | AZ628 | GDSC1000 | pan-cancer | AAC | -0.075 | 0.1 |
| mRNA | OSU-03012 | GDSC1000 | pan-cancer | AAC | 0.053 | 0.1 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | 0.049 | 0.1 |